Watch TLSI. Know when insiders buy.
One email the day a filing lands. Free.
TLSI
TriSalus Life Sciences, Inc.
4.15
−0.16 −3.71%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
57
WATCH · shorts 57
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $255.5MP/E —DIV YIELD —FCF YIELD -9.11%REV TTM $45.1M +25.2%NET INCOME −$28.2MNET CASH $13.2M52W 2.52 – 7.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $11.4M | +1.7% | 86.8% | −$9.8M | −$9.2M | — | -0.16 | −$10.1M | $82K | −$10.2M | Aug 6 |
| Q1 2026 · Mar 31 | $8.9M | −2.9% | 86.2% | −$8.4M | $1.5M | — | 0.03 | −$6.5M | $141K | −$6.6M | Aug 6 |
| Q4 2025 · Dec 31derived | $13.2M | +59.8% | 86.7% | −$3.3M | −$9.8M | — | -0.12 | −$2.5M | $41K | −$2.5M | Mar 5 |
| Q3 2025 · Sep 30 | $11.6M | +57.4% | 83.5% | −$9M | −$10.8M | — | -0.96 | −$3.7M | $216K | −$3.9M | Nov 13 |
| Q2 2025 · Jun 30 | $11.2M | +52.3% | 83.9% | −$7.3M | −$8.3M | — | -0.27 | −$7.3M | −$93K | −$7.2M | Aug 6 |
| Q1 2025 · Mar 31 | $9.2M | +42.0% | 83.7% | −$7.3M | −$10.4M | — | -0.39 | −$4.5M | $754K | −$5.3M | Aug 6 |
| Q4 2024 · Dec 31derived | $8.3M | +44.4% | 85.3% | −$7.6M | −$10.1M | — | -0.40 | −$5.7M | $50K | −$5.8M | Mar 5 |
| Q3 2024 · Sep 30 | $7.3M | +41.5% | 86.3% | −$8.7M | −$2.4M | — | -0.12 | −$10.8M | $169K | −$11M | Nov 13 |
| Q2 2024 · Jun 30 | $7.4M | — | 87.6% | −$8.2M | −$4.3M | — | -0.21 | −$13.4M | $60K | −$13.5M | Nov 13 |
| Q1 2024 · Mar 31 | $6.5M | — | 85.0% | −$11.7M | −$13.2M | — | -0.60 | −$10.9M | $66K | −$10.9M | Nov 13 |
| Q4 2023 · Dec 31derived | $5.7M | — | 89.8% | −$14.2M | −$35.6M | — | -1.05 | −$9.2M | $372K | −$9.5M | May 30 |
| Q3 2023 · Sep 30 | $5.2M | — | 88.7% | −$18.6M | −$1.4M | — | -0.14 | −$21.7M | $178K | −$21.8M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $45.2M | 84.6% | −$26.9M | −$39.2M | -86.9% | -1.84 | −$18M | $918K | −$18.9M | — | — |
| FY2024 · to Dec 31 | $29.4M | 86.1% | −$36.2M | −$30M | -102.1% | -1.31 | −$40.8M | $345K | −$41.2M | — | — |
| FY2023 · to Dec 31 | $18.5M | 85.9% | −$54.5M | −$59.4M | -320.7% | -6.77 | −$50.6M | $588K | −$51.2M | — | — |
| FY2022 · to Dec 31 | $12.4M | 81.8% | −$36.4M | −$47.2M | -380.6% | -161.55 | −$32.3M | $655K | −$33M | $232.4M | — |
| FY2021 · to Dec 31 | — | — | −$3M | $4.8M | — | — | −$1.7M | — | — | — | — |
Every number comes from TriSalus Life Sciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.